Symptomatic neurogenic orthostatic hypotension represents a clinically significant presentation requiring a specific pharmacological strategy. This first-line protocol defines the evidence-based approach for this patient population.
This protocol is indicated for patients with symptomatic neurogenic orthostatic hypotension — a distinct presentation in which standing triggers a symptomatic blood pressure drop of neurogenic origin.
The first-line pharmacological strategy involves an agent that functions as a norepinephrine precursor, exerting both central and peripheral alpha/beta-agonist activity to support blood pressure on standing.
The primary target is a modest increase in standing systolic blood pressure within approximately 2 weeks of treatment initiation, with accompanying improvement in symptom-related quality of life.
DOI: 10.1093/eurheartj/ehy037
Droxidopa, a precursor of norepinephrine, is a centrally and peripherally acting alpha/beta-agonist approved by the US Food and Drug Administration for the treatment of symptomatic neurogenic OH.
They showed a modest increase in standing systolic BP and the symptom benefit of droxidopa over placebo regarding some items of quality of life after 2 weeks of treatment, but its benefit was lost after 8 weeks.
View source ↗